Corbus Pharmaceuticals

CRBP

Market cap $166M

CRBP Hedge Fund Activity: Q1 2026 in Review

107 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2026, worth a combined $120M — up 12% from $108M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CRBP positions and 13 closed out — a net gain of 11 holders — while 33 added to existing stakes and 22 trimmed.

The largest buyer was Diadema Partners, opening a new position worth an estimated $3.7M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $7.77M sold.

• 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2026, up from 100 in Q4 2025.
• Funds reported $120M of Corbus Pharmaceuticals stock for Q1 2026, up 12% quarter-over-quarter.
• 24 funds opened new Corbus Pharmaceuticals positions in Q1 2026 and 13 closed out, a net change of +11 holders.
• The largest Corbus Pharmaceuticals buyer in Q1 2026 was Diadema Partners, an estimated $3.7M added.
• The largest Corbus Pharmaceuticals seller in Q1 2026 was Octagon Capital Advisors, an estimated $7.77M sold.

Based on aggregated 13F filings for Q1 2026.